MedTrace Logo

Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue

NCT05751720 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-01-12

No results posted yet for this study

Summary

Obesity and type 2 Diabetes Mellitus prevalence has doubled in the last 30 years and nearly one fifth of UAE population has Type 2 Diabetes while more than quarter has obesity.

Non-alcoholic fatty liver disease is present in more than 30% of patients with type 2 diabetes and in \> 50% patient with obesity

20% of patients with Non-alcoholic fatty liver disease progress to develop non-alcoholic steatohepatitis which can lead to liver failure and hepatocellular carcinoma.

This study aims to use GLP-1 analogue to see effects on liver fat deposition after six months of treatment

There is no current randomised study on treatment of non-alcoholic steatohepatitis in United Arab Emirates population; so once completed this will the first study.

This study will pave the way for developing a treatment pathway for patients with non-alcoholic fatty liver disease.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Non-alcoholic Steatohepatitis
  • Type 2 Diabetes
  • Liver Fat

Interventions

DRUG

GIP/GLP-1a

The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.

Sponsors & Collaborators

  • Dr Adnan Agha

    lead OTHER

Principal Investigators

  • Adnan Agha, FRCP · United Arab Emirates University, College of Medicine & Health Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2024-10-31
Completion
2025-02-28

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05751720 on ClinicalTrials.gov